| 126.73 -1.13 (-0.88%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 163.31 | 1-year : | 173.03 |
| Resists | First : | 139.82 | Second : | 148.14 |
| Pivot price | 135.99  |
|||
| Supports | First : | 126.34 | Second : | 105.12 |
| MAs | MA(5) : | 130.52 |
MA(20) : | 137.61 |
| MA(100) : | 133.11 |
MA(250) : | 113.94  |
|
| MACD | MACD : | -3 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 13 |
D(3) : | 23.7 |
| RSI | RSI(14): 32.2 |
|||
| 52-week | High : | 148.14 | Low : | 78.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NVO ] has closed above bottom band by 8.3%. Bollinger Bands are 98.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 128.53 - 129.31 | 129.31 - 129.88 |
| Low: | 124.5 - 125.53 | 125.53 - 126.3 |
| Close: | 125.38 - 126.9 | 126.9 - 128.02 |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Fri, 26 Jul 2024
FDA issues warning on compounded versions of Novo Nordisk's semaglutide (NYSE:NVO) - Seeking Alpha
Fri, 26 Jul 2024
Novo Nordisk’s ($NVO) Wegovy Gets EU Support to Expand Its Use - TipRanks
Fri, 26 Jul 2024
Novo Nordisk: Better Buying Opportunities Ahead (NYSE:NVO) - Seeking Alpha
Fri, 26 Jul 2024
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings? - Yahoo Finance
Thu, 25 Jul 2024
Novo Nordisk's Options Frenzy: What You Need to Know - Quantisnow
Wed, 24 Jul 2024
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4,450 (M) |
| Shares Float | 3,190 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.7 (%) |
| Shares Short | 4,520 (K) |
| Shares Short P.Month | 4,480 (K) |
| EPS | 2.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.18 |
| Profit Margin | 36.5 % |
| Operating Margin | 48.7 % |
| Return on Assets (ttm) | 25.2 % |
| Return on Equity (ttm) | 99.8 % |
| Qtrly Rev. Growth | 22.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 54.88 |
| EBITDA (p.s.) | 26.48 |
| Qtrly Earnings Growth | 29.3 % |
| Operating Cash Flow | 93,410 (M) |
| Levered Free Cash Flow | 40,240 (M) |
| PE Ratio | 43.4 |
| PEG Ratio | 99.9 |
| Price to Book value | 5.71 |
| Price to Sales | 2.3 |
| Price to Cash Flow | 6.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|